Symbols / MDXG
MDXG Chart
About
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 792.35M |
| Enterprise Value | 668.48M | Income | 40.83M | Sales | 393.44M |
| Book/sh | 1.61 | Cash/sh | 0.96 | Dividend Yield | — |
| Payout | 0.00% | Employees | 837 | IPO | — |
| P/E | 19.81 | Forward P/E | 37.54 | PEG | — |
| P/S | 2.01 | P/B | 3.31 | P/C | — |
| EV/EBITDA | 9.74 | EV/Sales | 1.70 | Quick Ratio | 3.82 |
| Current Ratio | 4.41 | Debt/Eq | 7.62 | LT Debt/Eq | — |
| EPS (ttm) | 0.27 | EPS next Y | 0.14 | EPS Growth | 113.80% |
| Revenue Growth | 35.30% | Earnings | 2026-02-25 | ROA | 11.98% |
| ROE | 19.44% | ROIC | — | Gross Margin | 81.99% |
| Oper. Margin | 19.51% | Profit Margin | 10.38% | Shs Outstand | 148.10M |
| Shs Float | 117.36M | Short Float | 6.04% | Short Ratio | 7.02 |
| Short Interest | — | 52W High | 8.46 | 52W Low | 4.89 |
| Beta | 1.59 | Avg Volume | 879.58K | Volume | 572.25K |
| Target Price | $9.67 | Recom | Strong_buy | Prev Close | $5.33 |
| Price | $5.35 | Change | 0.38% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.67
Mean price target
2. Current target
$5.35
Latest analyst target
3. DCF / Fair value
$6.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.35
Low
$8.00
High
$10.00
Mean
$9.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | init | Citizens | — → Market Outperform | $10 |
| 2026-02-17 | main | Cantor Fitzgerald | Overweight → Overweight | $8 |
| 2026-01-20 | main | Lake Street | Buy → Buy | $10 |
| 2025-12-17 | main | Mizuho | Outperform → Outperform | $10 |
| 2025-07-31 | main | Cantor Fitzgerald | Overweight → Overweight | $12 |
| 2025-07-15 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2025-02-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $13 |
| 2024-08-01 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2024-08-01 | main | Craig-Hallum | Buy → Buy | $12 |
| 2024-07-02 | init | Cantor Fitzgerald | — → Overweight | $11 |
| 2024-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-03-07 | init | Lake Street | — → Buy | $12 |
| 2024-03-01 | main | Mizuho | Buy → Buy | $14 |
| 2023-10-31 | main | Mizuho | Buy → Buy | $12 |
| 2023-10-27 | init | Craig-Hallum | — → Buy | $12 |
| 2023-08-02 | main | Mizuho | Buy → Buy | $12 |
| 2023-08-02 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-06-21 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-05-03 | main | HC Wainwright & Co. | — → Buy | $10 |
| 2023-03-02 | reit | HC Wainwright & Co. | — → Buy | $8 |
- MiMedx Group, Inc (MDXG) Stock Analysis: Exploring an 81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews ue, 24 Feb 2026 12
- New Analyst Forecast: $MDXG Given $10 Price Target - Quiver Quantitative Mon, 23 Feb 2026 10
- Citizens Initiates Coverage of MiMedx Group (MDXG) with Market Outperform Recommendation - Nasdaq Mon, 23 Feb 2026 11
- MiMedx Group (MDXG): Citizens Initiates Coverage with Market Out - GuruFocus Mon, 23 Feb 2026 13
- How The MiMedx (MDXG) Investment Story Is Resetting Around CMS And Analyst Revisions - Yahoo Finance Singapore Mon, 23 Feb 2026 05
- What to Expect from MiMedx Group's Earnings - Benzinga ue, 24 Feb 2026 19
- Wound and surgical grafts behind nearly 100 studies hit 15 years - Stock Titan Mon, 02 Feb 2026 08
- Citizens initiates MiMedx stock with outperform on reimbursement outlook - Investing.com South Africa Mon, 23 Feb 2026 08
- MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture - simplywall.st hu, 06 Nov 2025 08
- MiMedx Group, Inc (MDXG) Stock Analysis: A Biotech Gem With An 87.5% Potential Upside - DirectorsTalk Interviews ue, 17 Feb 2026 12
- Assessing MiMedx Group (MDXG) Valuation as Shares Show Renewed Momentum - Yahoo Finance hu, 30 Oct 2025 07
- This MiMedx Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga Mon, 23 Feb 2026 11
- MiMedx Group, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative ue, 17 Feb 2026 13
- Craig-Hallum Adjusts MiMedx Group, Inc. (MDXG) Outlook on CMS Coverage Guidance - Yahoo Finance Mon, 02 Feb 2026 08
- Beyond The Numbers: 4 Analysts Discuss MiMedx Group Stock - Benzinga Mon, 23 Feb 2026 12
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 58300 | 432329 | — | Sale at price 7.42 per share. | MAERSK-MOLLER KIMBERLY | Officer | — | 2025-11-06 00:00:00 | D |
| 1 | 28609 | 185100 | — | Stock Award(Grant) at price 6.47 per share. | BEHRENS M KATHLEEN | Director | — | 2025-06-18 00:00:00 | D |
| 2 | 28609 | 185100 | — | Stock Award(Grant) at price 6.47 per share. | BIERMAN JAMES L | Director | — | 2025-06-18 00:00:00 | D |
| 3 | 28609 | 185100 | — | Stock Award(Grant) at price 6.47 per share. | PUHY DOROTHY E | Director | — | 2025-06-18 00:00:00 | D |
| 4 | 28609 | 185100 | — | Stock Award(Grant) at price 6.47 per share. | OLSON TIFFANY | Director | — | 2025-06-18 00:00:00 | D |
| 5 | 28609 | 185100 | — | Stock Award(Grant) at price 6.47 per share. | LAURENCIN CATO T | Director | — | 2025-06-18 00:00:00 | D |
| 6 | 28609 | 185100 | — | Stock Award(Grant) at price 6.47 per share. | HAWKINS WILLIAM A III | Director | — | 2025-06-18 00:00:00 | D |
| 7 | 200000 | 1268000 | — | Purchase at price 6.34 per share. | CAPPER JOSEPH H | Chief Executive Officer | — | 2025-05-02 00:00:00 | D |
| 8 | 1759 | 14142 | — | Sale at price 8.04 per share. | KIMBERLY MAERSK-MOLLER | Officer | — | 2025-03-17 00:00:00 | D |
| 9 | 54596 | 430762 | — | Sale at price 7.89 per share. | HULSE WILLIAM FRANK IV | General Counsel | — | 2025-03-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -119.08K | 0.00 | 0.00 | -14.31K |
| TaxRateForCalcs | 0.27 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | 64.79M | 40.52M | -10.69M | -1.84M |
| TotalUnusualItems | -446.00K | 0.00 | 0.00 | -53.00K |
| TotalUnusualItemsExcludingGoodwill | -446.00K | 0.00 | 0.00 | -53.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 42.00M | 67.44M | -19.95M | -12.30M |
| ReconciledDepreciation | 6.04M | 3.43M | 4.05M | 5.18M |
| ReconciledCostOfRevenue | 54.80M | 51.97M | 44.97M | 35.27M |
| EBITDA | 64.34M | 40.52M | -10.69M | -1.89M |
| EBIT | 58.30M | 37.09M | -14.73M | -7.07M |
| NetInterestIncome | -1.01M | -6.46M | -5.02M | -4.98M |
| InterestExpense | 1.01M | 6.46M | 5.02M | 4.98M |
| NormalizedIncome | 42.32M | 67.44M | -19.95M | -12.26M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 42.42M | 58.23M | -30.20M | -12.30M |
| TotalExpenses | 289.57M | 284.36M | 282.57M | 249.02M |
| TotalOperatingIncomeAsReported | 58.87M | 37.12M | -14.73M | -7.05M |
| DilutedAverageShares | 149.05M | 145.96M | 112.91M | 110.35M |
| BasicAverageShares | 146.98M | 116.50M | 112.91M | 110.35M |
| DilutedEPS | 0.28 | 0.37 | -0.33 | -0.15 |
| BasicEPS | 0.29 | 0.40 | -0.33 | -0.15 |
| DilutedNIAvailtoComStockholders | 42.42M | 46.59M | -36.78M | -18.44M |
| NetIncomeCommonStockholders | 42.42M | 46.59M | -36.78M | -18.44M |
| OtherunderPreferredStockDividend | 0.00 | 4.89M | 0.00 | 926.00K |
| PreferredStockDividends | 6.75M | 6.58M | 5.21M | |
| NetIncome | 42.42M | 58.23M | -30.20M | -12.30M |
| NetIncomeIncludingNoncontrollingInterests | 42.42M | 58.23M | -30.20M | -12.30M |
| NetIncomeDiscontinuousOperations | 421.00K | -9.21M | -10.24M | |
| NetIncomeContinuousOperations | 42.00M | 67.44M | -19.95M | -12.30M |
| TaxProvision | 15.30M | -36.81M | 206.00K | 247.00K |
| PretaxIncome | 57.29M | 30.63M | -19.75M | -12.05M |
| OtherIncomeExpense | -1.01M | -26.00K | -4.00K | -76.00K |
| OtherNonOperatingIncomeExpenses | -565.00K | -26.00K | -4.00K | -23.00K |
| SpecialIncomeCharges | -446.00K | 0.00 | 0.00 | -53.00K |
| ImpairmentOfCapitalAssets | 446.00K | 0.00 | 0.00 | 53.00K |
| NetNonOperatingInterestIncomeExpense | -1.01M | -6.46M | -5.02M | -4.98M |
| InterestExpenseNonOperating | 1.01M | 6.46M | 5.02M | 4.98M |
| OperatingIncome | 59.31M | 37.12M | -14.73M | -7.00M |
| OperatingExpense | 229.50M | 229.73M | 234.25M | 209.39M |
| OtherOperatingExpenses | -8.70M | 5.18M | 12.18M | 3.79M |
| DepreciationAmortizationDepletionIncomeStatement | 765.00K | 762.00K | 701.00K | 820.00K |
| DepreciationAndAmortizationInIncomeStatement | 765.00K | 762.00K | 701.00K | 820.00K |
| Amortization | 765.00K | 762.00K | 701.00K | 820.00K |
| AmortizationOfIntangiblesIncomeStatement | 765.00K | 762.00K | 701.00K | 820.00K |
| ResearchAndDevelopment | 12.34M | 12.66M | 12.70M | 9.93M |
| SellingGeneralAndAdministration | 225.09M | 211.12M | 208.67M | 194.85M |
| GrossProfit | 288.81M | 266.84M | 219.53M | 202.39M |
| CostOfRevenue | 60.07M | 54.63M | 48.32M | 39.63M |
| TotalRevenue | 348.88M | 321.48M | 267.84M | 242.02M |
| OperatingRevenue | 348.88M | 321.48M | 267.84M | 242.02M |
| Line Item | 2023-12-31 | 2021-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 778.71K | ||
| PreferredSharesNumber | 100.00K | 100.00K | ||
| OrdinarySharesNumber | 146.93M | 146.23M | 113.71M | 111.93M |
| ShareIssued | 146.93M | 146.23M | 113.71M | 112.70M |
| TotalDebt | 18.83M | 49.10M | 48.59M | 48.13M |
| TangibleBookValue | 162.04M | 118.02M | -43.28M | -25.28M |
| InvestedCapital | 211.94M | 191.82M | 30.61M | 48.21M |
| WorkingCapital | 146.29M | 118.25M | 90.64M | 106.17M |
| NetTangibleAssets | 162.04M | 118.02M | -43.28M | -25.28M |
| CommonStockEquity | 193.11M | 142.72M | -17.99M | 82.00K |
| PreferredStockEquity | 92.49M | |||
| TotalCapitalization | 210.94M | 190.82M | 30.61M | 48.21M |
| TotalEquityGrossMinorityInterest | 193.11M | 142.72M | -17.99M | 82.00K |
| StockholdersEquity | 193.11M | 142.72M | -17.99M | 82.00K |
| TreasuryStock | 0.00 | 0.00 | 4.02M | |
| RetainedEarnings | -91.26M | -133.68M | -191.91M | -161.71M |
| AdditionalPaidInCapital | 284.22M | 276.25M | 173.80M | 165.69M |
| CapitalStock | 147.00K | 146.00K | 114.00K | 113.00K |
| CommonStock | 147.00K | 146.00K | 114.00K | 113.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 70.81M | 96.33M | 189.42M | 187.85M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 25.21M | 50.32M | 145.86M | 145.49M |
| OtherNonCurrentLiabilities | 7.38M | 2.22M | 4.77M | 4.87M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 92.49M | 92.49M | |
| LongTermDebtAndCapitalLeaseObligation | 17.83M | 48.10M | 48.59M | 48.13M |
| LongTermDebt | 17.83M | 48.10M | 48.59M | 48.13M |
| CurrentLiabilities | 45.59M | 46.01M | 43.56M | 42.36M |
| OtherCurrentLiabilities | 3.09M | 4.25M | 3.31M | 1.56M |
| CurrentDebtAndCapitalLeaseObligation | 1.00M | 1.00M | ||
| CurrentDebt | 1.00M | 1.00M | ||
| OtherCurrentBorrowings | 1.00M | 1.00M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 23.67M | 22.35M | 20.86M | 23.59M |
| PayablesAndAccruedExpenses | 17.84M | 18.41M | 19.39M | 17.20M |
| CurrentAccruedExpenses | 9.01M | 9.36M | 10.93M | 9.81M |
| Payables | 8.83M | 9.05M | 8.45M | 7.38M |
| OtherPayable | 1.42M | |||
| AccountsPayable | 7.41M | 9.05M | 8.45M | 7.38M |
| TotalAssets | 263.92M | 239.05M | 171.43M | 187.93M |
| TotalNonCurrentAssets | 72.03M | 74.79M | 37.23M | 39.41M |
| OtherNonCurrentAssets | 1.11M | 205.00K | 683.00K | 186.00K |
| NonCurrentDeferredAssets | 28.31M | 40.78M | 0.00 | |
| NonCurrentDeferredTaxesAssets | 28.31M | 40.78M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 31.07M | 24.70M | 25.29M | 25.36M |
| OtherIntangibleAssets | 11.63M | 5.26M | 5.85M | 5.38M |
| Goodwill | 19.44M | 19.44M | 19.44M | 19.98M |
| NetPPE | 11.55M | 9.11M | 11.26M | 13.86M |
| AccumulatedDepreciation | -21.32M | -20.03M | -35.93M | -32.88M |
| GrossPPE | 32.87M | 29.13M | 47.18M | 46.74M |
| Leases | 8.21M | 8.14M | 9.19M | 9.05M |
| ConstructionInProgress | 686.00K | 1.79M | 1.98M | 397.00K |
| OtherProperties | 22.02M | 17.21M | 20.99M | 22.32M |
| MachineryFurnitureEquipment | 1.95M | 1.99M | 15.02M | 14.97M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 191.89M | 164.26M | 134.20M | 148.52M |
| OtherCurrentAssets | 2.82M | 1.75M | 3.33M | 2.81M |
| AssetsHeldForSaleCurrent | 0.00 | 1.33M | ||
| PrepaidAssets | 5.02M | 5.62M | 7.32M | 6.15M |
| Inventory | 23.81M | 21.02M | 13.18M | 11.39M |
| FinishedGoods | 14.22M | 11.68M | 5.52M | 4.91M |
| WorkInProcess | 8.58M | 8.52M | 6.86M | 6.11M |
| RawMaterials | 1.01M | 825.00K | 810.00K | 364.00K |
| Receivables | 55.83M | 53.87M | 43.08M | 41.10M |
| TaxesReceivable | 704.00K | 743.00K | ||
| AccountsReceivable | 55.83M | 53.87M | 43.08M | 40.35M |
| AllowanceForDoubtfulAccountsReceivable | -3.13M | -3.14M | -3.78M | -1.19M |
| GrossAccountsReceivable | 58.96M | 57.02M | 46.87M | 41.54M |
| CashCashEquivalentsAndShortTermInvestments | 104.42M | 82.00M | 65.95M | 87.08M |
| CashAndCashEquivalents | 104.42M | 82.00M | 65.95M | 87.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 64.52M | 24.79M | -19.41M | -5.20M |
| RepurchaseOfCapitalStock | -2.64M | -9.52M | -1.19M | -4.75M |
| RepaymentOfDebt | -81.50M | 0.00 | 0.00 | -38.00K |
| IssuanceOfDebt | 49.78M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -1.68M | -1.99M | -1.51M | -3.22M |
| InterestPaidSupplementalData | 2.70M | 6.03M | 4.57M | 4.33M |
| IncomeTaxPaidSupplementalData | 3.25M | 181.00K | 169.00K | |
| EndCashPosition | 104.42M | 82.00M | 65.95M | 87.08M |
| BeginningCashPosition | 82.00M | 65.95M | 87.08M | 95.81M |
| ChangesInCash | 22.42M | 16.05M | -21.13M | -8.73M |
| FinancingCashFlow | -34.20M | -8.57M | -580.00K | -3.35M |
| CashFlowFromContinuingFinancingActivities | -34.20M | -8.57M | -580.00K | -3.35M |
| NetOtherFinancingCharges | -1.24M | -52.00K | -41.00K | |
| ProceedsFromStockOptionExercised | 1.40M | 997.00K | 651.00K | 1.44M |
| NetPreferredStockIssuance | 0.00 | -9.52M | 0.00 | 0.00 |
| PreferredStockPayments | 0.00 | -9.52M | 0.00 | 0.00 |
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | -2.64M | 0.00 | -1.19M | -4.75M |
| CommonStockPayments | -2.64M | 0.00 | -1.19M | -4.75M |
| NetIssuancePaymentsOfDebt | -31.72M | 0.00 | 0.00 | -38.00K |
| NetLongTermDebtIssuance | -31.72M | 0.00 | 0.00 | -38.00K |
| LongTermDebtPayments | -81.50M | 0.00 | 0.00 | -38.00K |
| LongTermDebtIssuance | 49.78M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | -9.58M | -2.15M | -2.66M | -3.40M |
| CashFlowFromContinuingInvestingActivities | -9.58M | -2.15M | -2.66M | -3.40M |
| NetOtherInvestingChanges | -38.00K | -168.00K | -1.15M | -177.00K |
| NetBusinessPurchaseAndSale | -7.86M | 0.00 | 0.00 | |
| PurchaseOfBusiness | -7.86M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | -1.00M | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -1.00M | 0.00 | |
| NetPPEPurchaseAndSale | -1.68M | -1.99M | -1.51M | -3.22M |
| SaleOfPPE | 0.00 | 24.00K | 0.00 | |
| PurchaseOfPPE | -1.68M | -1.99M | -1.51M | -3.22M |
| OperatingCashFlow | 66.20M | 26.77M | -17.89M | -1.98M |
| CashFromDiscontinuedOperatingActivities | -930.00K | -8.16M | -9.92M | 7.89M |
| CashFlowFromContinuingOperatingActivities | 67.13M | 34.94M | -7.97M | -9.87M |
| ChangeInWorkingCapital | -5.43M | -18.42M | -8.01M | -19.35M |
| ChangeInOtherWorkingCapital | -1.83M | 1.04M | -258.00K | 14.43M |
| ChangeInOtherCurrentLiabilities | -497.00K | 38.00K | -1.16M | |
| ChangeInOtherCurrentAssets | 1.53M | -333.00K | 9.98M | |
| ChangeInPayablesAndAccruedExpense | 697.00K | 904.00K | 1.35M | -15.65M |
| ChangeInAccruedExpense | 2.11M | 121.00K | 507.00K | -15.49M |
| ChangeInPayable | -1.41M | 783.00K | 839.00K | -159.00K |
| ChangeInAccountPayable | -1.41M | 783.00K | 839.00K | -159.00K |
| ChangeInPrepaidAssets | 606.00K | -283.00K | -1.37M | -501.00K |
| ChangeInInventory | -2.36M | -7.84M | -1.79M | -1.41M |
| ChangeInReceivables | -2.55M | -12.24M | -5.94M | -10.62M |
| ChangesInAccountReceivables | -12.24M | -5.55M | -10.62M | |
| OtherNonCashItems | -6.88M | 1.88M | 1.80M | 2.12M |
| StockBasedCompensation | 16.93M | 16.96M | 11.33M | 14.16M |
| ProvisionandWriteOffofAssets | 595.00K | 1.45M | 2.82M | |
| AssetImpairmentCharge | 1.45M | 2.82M | 53.00K | |
| DeferredTax | 12.47M | -37.80M | 0.00 | 0.00 |
| DeferredIncomeTax | 12.47M | -37.80M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 6.04M | 3.43M | 4.05M | 5.18M |
| DepreciationAndAmortization | 6.04M | 3.43M | 4.05M | 5.18M |
| AmortizationCashFlow | 3.76M | 762.00K | 701.00K | 820.00K |
| AmortizationOfIntangibles | 3.76M | 762.00K | 701.00K | 820.00K |
| Depreciation | 2.28M | 2.67M | 3.35M | 4.36M |
| OperatingGainsLosses | 1.40M | 15.00K | -17.00K | 262.00K |
| GainLossOnSaleOfPPE | 15.00K | -17.00K | 262.00K | |
| NetIncomeFromContinuingOperations | 42.00M | 67.44M | -19.95M | -12.30M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MDXG
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|